Skip to content

Trial · Interventional

CompletedPhase 3Results postedRegistry data

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Short name ELECT

NCTNCT00774930 (opens ClinicalTrials.gov in a new tab)Other id2-55-52030-730Other idTR321Other id2010-019066-92

Overview

Status
Completed
Phase
Phase 3
Enrollment
115 participants (actual)
Sponsor
Ipsen · Industry
Design
Randomized · Double masking
Countries
11 countries

United States, Brazil, Czechia, India, Latvia, Poland, Russia, Serbia, South Africa, Turkey (Türkiye), Ukraine

Start
May 2009
Primary completion
May 2013
Completion
Dec 2015
First posted
17 Oct 2008 (estimated)
Last update posted
14 Oct 2022
Conditions
Carcinoid Syndrome

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2010201220142016
  1. Ph 3

    ELECT

    NCT00774930

    May 2009 to Dec 2015

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.

Interventions

  • LanreotideDrug
  • PlaceboDrug

Arms2

  • Experimental

    Lanreotide Autogel (Somatuline Depot) 120 mg

    Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase). After completing the DB phase (or if they met criteria for early roll over \[ERO\]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained \[whichever occurred first\]).

  • Placebo comparator

    Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE

    Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase). After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained \[whichever occurred first\]).

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Percentage of Days With Subcutaneous Octreotide as Rescue Medication

    Time frame · 16-week DB phase

    Registry description

    Use of s.c. octreotide required to control symptoms associated with carcinoid syndrome, measured as the percentage of days that s.c. octreotide was used as rescue medication, based on subject Interactive Voice Response System (IVRS) or Interactive Web Response System (IWRS) diary records.

Secondary outcomes(9)
  1. Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.

    Time frame · 16-week DB phase

  2. Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.

    Time frame · 16-week DB phase

  3. Percentage of Days of Use of Other Rescue Medication

    Time frame · 16-week DB phase

    Registry description

    Usage of other concomitant rescue medications for diarrhoea and/or flushing events, measured as the percentage of days that the medications were used as rescue medication based on subject IVRS/IWRS diary records. Subjects were required to record the use and dose of s.c. octreotide, if any, as well as the use of other concomitant rescue medications (e.g. loperamide 2 mg tabs, and/or tincture of opium).

  4. Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study

    Time frame · 16-week DB phase

    Registry description

    Subjects who rolled over early were those who received less than four DB injections before receiving the first IOL injection.

  5. Changes From Baseline in "Global Health Status/Quality of Life (QoL)" Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30)

    Time frame · Baseline and Week 12 of DB phase

    Registry description

    Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. Q29 and Q30 range from 1 (Very poor) to 7 (Excellent) with 1 being worst case and 7 the most favourable answer. Scores were derived according to the rules contained within the EORTC scoring manual. All of the scores range in score from 0 to 100. A high score for global health status/QoL represents high QoL. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. Raw score = RS = (I1 + I2 +…+ In)/n. For global health status/QoL: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.

  6. Changes From Baseline in "Gastrointestinal (G.I). Symptoms" Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21]

    Time frame · Baseline and Week 12 of DB phase

    Registry description

    Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n. For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.

  7. Changes From Baseline in QoL in "Endocrine Symptoms" Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires)

    Time frame · Baseline and Week 12 of DB phase

    Registry description

    Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment. The QLQ-G.I.NET21 questionnaire contains 21 single items (Q31 to Q51) which are supplemental items to the EORTC QLQ-C30 questionnaire. Q31 to Q51 range from 1 to 4 with 1 being the most favourable answer and 4 the worst case (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). Based on these items the scores were generated. All of the scores range in score from 0 to 100. A high score for a symptom scale represents a high level of symptomatology. The principle for scoring the scale is: Estimate the average of the items (I1, I2, ..., In) that contribute to the scale; this is the raw score. RS = (I1 + I2 +…+ In)/n. For symptom scales: Score = {(RS - 1)/range} x 100, where range is the difference between the maximum possible value of RS and the minimum possible value of RS.

  8. Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA])

    Time frame · Baseline and Week 12 of DB phase

    Registry description

    Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.

  9. Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA])

    Time frame · Baseline and Week 12 of DB phase

    Registry description

    Baseline is defined as the last non-missing observation obtained prior to the initiation of study treatment.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeLeast squares mean· 16-week DB phase

Percentage of Days With Subcutaneous Octreotide as Rescue Medication

GroupValue (Percentage of days)
Lanreotide Autogel (Somatuline Depot) 120 mg33.72
Placebo48.49
Secondary and other outcome results(7)
Secondary outcomeMean· 16-week DB phase

Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.

GroupValue (Number of events per day)Spread
Lanreotide Autogel (Somatuline Depot) 120 mg1.561.83
Placebo1.351.45
Secondary outcomeMean· 16-week DB phase

Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.

GroupValue (Number of events per day)Spread
Lanreotide Autogel (Somatuline Depot) 120 mg0.921.45
Placebo1.752.26
Secondary outcomeMean· 16-week DB phase

Percentage of Days of Use of Other Rescue Medication

GroupValue (Percentage of days)Spread
Lanreotide Autogel (Somatuline Depot) 120 mg8.8619.34
Placebo6.2517.48
Secondary outcomeNumber· 16-week DB phase

Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study

GroupValue (Percentage of subjects)
Lanreotide Autogel (Somatuline Depot) 120 mg18.6
Placebo21.4
Secondary outcomeMean· Baseline and Week 12 of DB phase

Changes From Baseline in "Global Health Status/Quality of Life (QoL)" Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30)

GroupValue (Units on a scale)Spread
Lanreotide Autogel (Somatuline Depot) 120 mg4.1714.18
Placebo-1.7218.21
Secondary outcomeMean· Baseline and Week 12 of DB phase

Changes From Baseline in "Gastrointestinal (G.I). Symptoms" Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21]

GroupValue (Units on a scale)Spread
Lanreotide Autogel (Somatuline Depot) 120 mg-4.0612.80
Placebo0.1013.83
Secondary outcomeMean· Baseline and Week 12 of DB phase

Changes From Baseline in QoL in "Endocrine Symptoms" Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires)

GroupValue (Units on a scale)Spread
Lanreotide Autogel (Somatuline Depot) 120 mg-6.8318.98
Placebo-2.6922.23

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Lanreotide Autogel (Somatuline Depot) 120 mg (DB Phase)Deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase.–2 / 5831 / 58
Placebo (DB Phase)Deep s.c. injections of placebo every 4 weeks (±3 days) for 16 weeks (DB phase). Subjects then received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks in the IOL phase and further deep s.c. injections with lanreotide Autogel every 4 weeks in the LTOLE phase.–5 / 5734 / 57
Lanreotide Autogel (Somatuline Depot) 120 mg (IOL Phase)All 101 subjects in the IOL phase received deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks for 32 weeks (56 and 45 of these subjects received treatment with lanreotide Autogel and placebo, respectively, during the DB phase).–8 / 10171 / 101
Lanreotide Autogel (Somatuline Depot) 120 mg (LTOLE Phase)All 57 subjects in the LTOLE phase received further deep s.c. injections of lanreotide Autogel 120 mg every 4 weeks (32 and 25 of these subjects received treatment with lanreotide Autogel and placebo, respectively, during the DB phase).–15 / 5746 / 57

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

2 studies on this page

PubMed tag: none · 2019

4 results

A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.

Blot et al. 2019Patient related outcome measurescited by 2

PMID 31754316PMC6825468DOI 10.2147/prom.s219982PUB-31754316

Free to read · publisher termsCC BY-NC4 results

Indexing hint: Randomized controlled trial · 2016

3 results

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

Vinik et al. 2016Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistscited by 73

PMID 27214300DOI 10.4158/ep151172.orPUB-27214300

Full text at the publisher3 results

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Subjects were eligible for participation in the study if they met the following criteria: 1. At least 18 years of age at the time of first dosing. 2. Subjects must have given signed informed consent before any study related activities were conducted. 3. Subjects in the United States of America (USA) must have given written authorisation for the release of protected health information in compliance with the Health Insurance Portability and Accountability Act (HIPAA) regulations; subjects in other countries must have provided appropriate authorisation as needed by regulatory authorities in each country. 4. Subjects must have been willing to receive s.c. octreotide injections as rescue medication, as needed to control their symptoms, if any. 5. If female, the subject must not have been pregnant (confirmed by negative pregnancy test) and must have had the following documented via verbally given history: * At least 1 year postmenopausal (natural cessation of menses), or * Surgically sterile (if by tubal ligation, surgery must have been performed more than 3 months prior to entry into the study), or * If the subject was of childbearing potential and sexually active, she must have been using an acceptable form of contraception (oral, injected, transdermal or implanted contraceptives, diaphragm or barrier method with spermicidal and/or intrauterine device); local methods such as condoms or sponges/vaginal tablets were not acceptable forms of contraception. 6. Subjects with a histopathologically confirmed diagnosis of carcinoid tumour or, a carcinoid tumour of unknown location with liver metastases (documented biopsy), and a history of carcinoid syndrome (flushing and/or diarrhoea) who were either naïve to treatment with a somatostatin analogue (SSTa) or responsive (according to the opinion of the principal investigator) to conventional doses of Sandostatin LAR® Depot (LAR; ≤30 mg every 4 weeks) or to daily doses of ≤600 μg of s.c. octreotide. 7. Confirmation of positive somatostatin receptor (SSTR) status by somatostatin receptor scintigraphy (SRS; up to 6 months prior to study entry at the Screening Visit). 8. Absence of tumour progression documented by two sequential computed tomography (CT) scans or two sequential magnetic resonance imaging (MRI) scans (≥3 months apart); the last CT or MRI scan must have been performed within 6 months of study entry (Screening Visit). 9. Subjects previously treated with LAR, must have received their last dose of LAR at least 4 weeks prior to first dose of study treatment (no later than at the Screening Visit). 10. Be able to communicate and cooperate with the principal investigator and the staff and willing to comply with the study instructions. Subjects were excluded from entering the study for the following reasons: 1. History of known allergy or hypersensitivity to investigational drug or any components of its formulation, or octreotide. 2. History of carcinoid syndrome refractory to treatment with conventional doses of SSTa. 3. Treatment with any other investigational drug within 30 days prior to study entry (Screening Visit) and/or at any time during the subject's participation in the study. 4. Treatment with interferon, chemotherapy and/or radiotherapy (a radiolabelled SSTa) and/or tumour debulking \<3 months prior to study entry (Screening Visit). 5. History of hepatic arterial embolisation, hepatic arterial chemoembolisation and/or selective internal radiation therapy (selective internal radiation \[SIR\] therapy \[SIRT\]; e.g. SIR Spheres) \<6 months prior to study entry (Screening Visit). 6. Short bowel syndrome. 7. Uncontrolled diabetes and/or hypertension. 8. Severe renal impairment (glomerular filtration rate \<30 mL/min/1.73 m2) and/or severe liver impairment as evidenced by serum total bilirubin \>1.5 mg/dL associated with bile duct blockage or with alkaline phosphatase (ALP), aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>5.0 upper limit of normal (ULN). 9. Diagnosis of cardiac disease New York Heart Association (NYHA) functional classification \>Class I. (Subject has limitation of physical activity. Ordinary physical activity causes undue fatigue, palpitation, or dyspnoea). 10. Life expectancy less than 1 year. 11. Any malignancies except carcinoid tumour, basocellular carcinoma of the skin, in situ carcinoma of the cervix and ≥5 years disease free after curative cancer treatment. 12. Any serious medical condition that could jeopardise the safety of the subject and/or the efficacy assessments of the study. 13. Subject is being treated with a proton pump inhibitor (PPI) and has been at a stable dose (no change in dose or frequency of administration) for less than 4 weeks at study entry (Screening Visit).

PepBank is a research reference. Talk to a doctor before you use any peptide.